There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation
in histones and other proteins and in regulating fundamental cellular activities such
as transcription. A wide range of brain disorders are associated with imbalances in
protein acetylation levels and transcriptional dysfunctions. Treatment with various
HDAC inhibitors can correct these deficiencies and has emerged as a promising new
strategy for therapeutic intervention in neurodegenerative disease. Here, we review
and discuss intriguing recent developments in the use of HDAC inhibitors to combat
neurodegenerative conditions in cellular and disease models. HDAC inhibitors have
neuroprotective, neurotrophic and anti-inflammatory properties; improvements in neurological
performance, learning/memory and other disease phenotypes are frequently seen in these
models. We discuss the targets and mechanisms underlying these effects of HDAC inhibition
and comment on the potential for some HDAC inhibitors to prove clinically effective
in the treatment of neurodegenerative disorders.